AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
AVITA Medical, Inc.NASDAQ: RCEL
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $627K rose 20.3% year over year, behind the +48.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 59.9% from the prior quarter. Over 3 fiscal years it compounded at +53.1% a year.
Context
- Depreciation & amortization amounted to 2.8% of revenue in FY2025, up 1.1 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +20.3% toward the trailing-twelve-month pace of +48.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.04M USD
- Year-over-year change
- +81.1%
- 4-year CAGR
- +20.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.04M | +81.1% |
| FY2024 | 2024-12-31 | 1.13M | +78.2% |
| FY2023 | 2023-12-31 | 632K | +11.3% |
| FY2022 | 2022-12-31 | 568K | -41.4% |
| FY2021 | 2021-12-31 | 969K | — |
Depreciation & Amortization vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's LTM Mar 2026 depreciation & amortization of $2.15M is the 5th largest of the 9 companies compared; the peer median is $2.51M.
- Its year-over-year change of +48.5% is the 2nd highest of 9, against a peer median of +10.6%.
- Depreciation & amortization amounts to 3.0% of revenue for RCEL, versus a peer median of 4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $429.44M | +48315.3% | -23.3% | 8364.7% | |
| LTM Mar 2026 | $4.68M | +9.1% | +59.3% | 3.8% | |
| LTM Mar 2026 | $4.61M | -17.9% | -18.0% | 4.4% | |
| LTM Mar 2026 | $3.64M | -3.9% | +6.3% | 364.3% | |
| LTM Mar 2026 | $2.15M | +48.5% | +53.1% | 3.0% | |
| LTM Mar 2026 | $1.38M | +41.1% | +2.4% | 9.0% | |
| LTM Mar 2026 | $719K | +24.0% | -9.7% | 1.3% | |
| LTM Mar 2026 | $452K | +12.2% | +3.6% | — | |
| LTM Mar 2026 | $168K | -72.2% | -41.8% | 2.4% | |
| Peer median (excluding RCEL) | $2.51M | +10.6% | -3.7% | 4.4% | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.14M) | (26.67M) | (35.38M) | (61.85M) | (48.59M) |
| Depreciation & Amortization | 969K | 568K | 632K | 1.13M | 2.04M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.33M | 7M | 8.38M | 13.5M | 9.52M |
| Change in Working Capital | (1.73M) | (1.2M) | (6.57M) | (4.68M) | 3.44M |
| Accounts Receivables | (1.19M) | (985K) | (3.3M) | (4.17M) | 3.63M |
| Inventory | (144K) | (371K) | (3.69M) | (2.16M) | (468K) |
| Accounts Payables | 0 | 282K | 809K | 340K | 2.75M |
| Other Working Capital | (391K) | (122K) | (386K) | 1.31M | (2.47M) |
| Other Non-Cash Items | 1.53M | 1.21M | (5.07M) | 2.96M | 2.4M |
| Operating Cash Flow | (18.04M) | (19.09M) | (38.01M) | (48.94M) | (31.2M) |
| Capital Expenditures | (487K) | (525K) | (1.45M) | (9.33M) | (1.74M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (74.36M) | (78.76M) | (24.5M) | (13.31M) |
| Sales of Investments | 0 | 55.56M | 81.81M | 71.2M | 27.5M |
| Other Investing Activities | (49.72M) | (73K) | (66K) | (162K) | (734K) |
| Investing Cash Flow | (50.21M) | (19.33M) | 1.61M | 37.36M | 12.45M |
| Debt Repayment | (11K) | 0 | 38.76M | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 14.14M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 64.08M | 900K | 1.61M | 3.51M | 795K |
| Financing Cash Flow | 64.07M | 900K | 40.37M | 3.51M | 14.94M |
| Effect of Forex Changes | 41.29M | (26K) | (16K) | 0 | 0 |
| Net Change in Cash | 37.11M | (37.55M) | 3.95M | (8.07M) | (3.81M) |
| Free Cash Flow | (18.52M) | (19.62M) | (39.46M) | (58.27M) | (32.93M) |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.